# Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder

> **NCT06116045** · PHASE2 · RECRUITING · sponsor: **Biozeus Biopharmaceutical S.A.** · enrollment: 30 (estimated)

## Conditions studied

- Female Sexual Arousal Disorder
- Female Sexual Dysfunction

## Interventions

- **DRUG:** BZ371A 7.5 mg (1.5 ml)
- **DRUG:** BZ371A 5.0 mg (1.0 ml)
- **DRUG:** BZ371A 2.5 mg (0.5 ml)
- **DRUG:** Placebo (1.5 ml)
- **DRUG:** Placebo (1.0 ml)
- **DRUG:** Placebo (0.5 ml)

## Key facts

- **NCT ID:** NCT06116045
- **Lead sponsor:** Biozeus Biopharmaceutical S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116045, "Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06116045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*